2. MAPK/ERK Pathway Protein Tyrosine Kinase/RTK Autophagy Apoptosis Stem Cell/Wnt JAK/STAT Signaling PI3K/Akt/mTOR Metabolic Enzyme/Protease Cytoskeleton Epigenetics Cell Cycle/DNA Damage
  3. Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family
  4. Sorafenib

Sorafénib (Bay 43-9006) est un inhibiteur de Raf qui est puissant et actif par voie orale avec des IC50 de 6 nM et 20 nM pour Raf-1 et B-Raf, respectivement. Sorafénib est un inhibiteur multikinase avec des IC50 de 90 nM, 15 nM, 20 nM, 57 nM et 58 nM pour VEGFR2, VEGFR3, PDGFRβ, FLT3 et c-Kit, respectivement. Sorafénib induit l'autophagie etl'apoptose. Sorafénib a une activité anti-tumorale. Sorafenib est un activateur de la ferroptose.

Sorafenib (Bay 43-9006) ist ein potenter und oral wirksamer Raf-Inhibitor mit IC50s von 6 nM bzw. 20 nM für Raf-1 und B-Raf. Sorafenib ist ein Multikinase-Inhibitor mit IC50s von 90 nM, 15 nM, 20 nM, 57 nM und 58 nM für VEGFR2, VEGFR3, PDGFRβ, FLT3 und c-Kit. Sorafenib induziert autophagy und apoptosis. Sorafenib hat antitumorale Aktivität. Sorafenib ist ein ferroptosis-Aktivator.

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.

For research use only. We do not sell to patients.

CAS No. : 284461-73-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 283 publication(s) in Google Scholar

Other Forms of Sorafenib:

Sorafenib Related Antibodies

Top Publications Citing Use of Products

283 Publications Citing Use of MCE Sorafenib

Cell Imaging/Staining
RT-PCR
WB
Histological Imaging/Staining
In Vivo Efficacy Study
Cell Proliferation/Viability Assay

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):87.  [Abstract]

    The cell viability of YAP-, YAP-S127A-, or YAP-R124F-overexpressed Huh-7 cells cultured in methionine-deprived medium (MD) and treated with sorafenib (1.5-3 μM) for 24 h.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101.  [Abstract]

    Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24.  [Abstract]

    Sorafenib tosylate (90-900 nM) markedly suppressed the upregulation of endothelial-like differentiation in ligament cells mediated by LOXL2.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24.  [Abstract]

    Sorafenib tosylate (50 mg/kg; i.g.; one daily for 14 d) significantly decreased bone volume (BV) in BMP-induced ossification mice.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24.  [Abstract]

    Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) caused sparse trabecular bone structures in BMP-induced ossification mice, accompanied by numerous cartilage structures and amorphous matrix deposition, indicating a delay in endochondral ossification.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24.  [Abstract]

    Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) significantly lowered the level of SP7 in BMP-induced ossification mice.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24.  [Abstract]

    Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d)caused a shorter response time to thermal stimulation and less paw withdrawal threshold to mechanical stimulation of BMP-induced ossification mice.

    Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258.  [Abstract]

    Western blot to detect the ferritin H protein level by the gain or loss of URB1-AS1 in sorafenib-sensitive or sorafenib-resistant HepG2 cells.

    Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258.  [Abstract]

    qPCR showing the nuclear and cytoplasmic fractions of URB1-AS1 in sorafenib-resistant HepG2 cells with β-actin and MALAT1 as cytoplasmic and nuclear controls, respectively.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.  [Abstract]

    PANC-1 cells were transfected with the recombinant plasmid for 24 h and treated with sorafenib (0–70 μmol/L) for another 24 h, and then total cellular extracts were subjected to Western blotting using antibodies against caspase-3, GSDME and β-tubulin.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2645-2662.

    HeLa and SiHa cells were treated with condition medium (CM) from human PBMC-derived M0 macrophages (Ctrl) and TAM. And then cells were treated with indicated dose of Sorafenib (Sora) for 48 h. Inhibition ratio of cell viability was detected by CCK-8 assay.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.  [Abstract]

    Sorafenib (12.5-125 μM; 24 h) inhibits the viability of PANC-1 cells in a dose-dependent manner.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83.  [Abstract]

    Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83.  [Abstract]

    Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585.  [Abstract]

    Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532.  [Abstract]

    SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983.  [Abstract]

    The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.

    Sorafenib purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229.  [Abstract]

    The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514.  [Abstract]

    VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123.  [Abstract]

    Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123.  [Abstract]

    Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W

    Sorafenib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784.  [Abstract]

    Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.  [Abstract]

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.  [Abstract]

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

    View All Raf Isoform Specific Products:

    View All Isoforms
    B-Raf C-Raf Raf

    View All VEGFR Isoform Specific Products:

    View All Isoforms
    VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

    View All STAT Isoform Specific Products:

    View All Isoforms
    STAT3 STAT5 STAT6 STAT1

    View All Akt Isoform Specific Products:

    View All Isoforms
    Akt Akt1 Akt2 Akt3

    View All MMP Isoform Specific Products:

    View All Isoforms
    MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

    View All p38 MAPK Isoform Specific Products:

    View All Isoforms
    p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

    View All ERK Isoform Specific Products:

    View All Isoforms
    ERK ERK1 ERK2 ERK5 ERK8

    View All MEK Isoform Specific Products:

    View All Isoforms
    MEK1 MEK2 MEK5 MEK MAP2K4/MEK4 MAP2K7/MEK7

    View All PI3K Isoform Specific Products:

    View All Isoforms
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    View All PARP Isoform Specific Products:

    View All Isoforms
    PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

    View All Bcl-2 Family Isoform Specific Products:

    View All Isoforms
    Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma[1][2][3][4][5][6].

    IC50 & Target[1][3][5]

    VEGFR3

    20 nM (IC50)

    Braf

    22 nM (IC50)

    Raf-1

    6 nM (IC50)

    VEGFR2

    15 nM (IC50)

    BrafV599E

    38 nM (IC50)

    STAT3

     

    MMP2

     

    Bcl-xL

     

    Bcl-2

     

    Cellular Effect
    Cell Line Type Value Description References
    786-0 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB method
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition
    Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    786-0 IC50
    13 μM
    Compound: Sora
    Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    786-0 IC50
    15.62 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    786-0 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    786-0 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    786-0 IC50
    4.9 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    		[PMID: 29297688]
    786-0 IC50
    4.9 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay
    		[PMID: 29517908]
    786-0 IC50
    5.3 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    		[PMID: 29786436]
    8505C IC50
    4.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay
    Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    A-375 IC50
    1.8 μM
    Compound: Sorafenib
    Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38354306]
    A-375 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    A-375 IC50
    10.28 μM
    Compound: Sorafenib
    Cytotoxicity against human A-375 cells by MTT assay
    Cytotoxicity against human A-375 cells by MTT assay
    		[PMID: 33316752]
    A-375 IC50
    13.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    A-375 IC50
    13.64 μM
    Compound: 3
    Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay
    		[PMID: 25462267]
    A-375 IC50
    13.64 μM
    Compound: Sorafenib
    Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    A-375 IC50
    16.24 μM
    Compound: Sorafenib
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461318]
    A-375 IC50
    2.4 μM
    Compound: 1
    Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras
    Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras
    		[PMID: 22808911]
    A-375 IC50
    2200 nM
    Compound: Sorafenib
    Toxicity against human A375 cells after 72 hrs by cell titer-blue assay
    Toxicity against human A375 cells after 72 hrs by cell titer-blue assay
    		[PMID: 19654408]
    A-375 IC50
    3.36 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    		[PMID: 29602674]
    A-375 IC50
    5.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    		[PMID: 20056548]
    A-375 IC50
    5.4 μM
    Compound: sorafenib
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    		[PMID: 18477505]
    A-375 IC50
    5.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells by MTT assay
    Antiproliferative activity against human A375 cells by MTT assay
    		[PMID: 19464887]
    A-375 IC50
    5.6 μM
    Compound: Sorafenib, Nexavar
    Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum
    Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum
    		[PMID: 21592628]
    A-375 IC50
    6599 nM
    Compound: 1, Nexavar
    Inhibition of BRAF V600E mutant-dependent MEK phosphorylation in A375 cells
    Inhibition of BRAF V600E mutant-dependent MEK phosphorylation in A375 cells
    		[PMID: 21807507]
    A-375 IC50
    7.56 μM
    Compound: Sorafenib
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    		[PMID: 24215818]
    A-375 IC50
    7.88 μM
    Compound: Sorafenib
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30955995]
    A-375 IC50
    8.27 μM
    Compound: 1
    Antiproliferative activity against human A375 cells
    Antiproliferative activity against human A375 cells
    		[PMID: 30216849]
    A-375 IC50
    8.33 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    		[PMID: 29886324]
    A-375 IC50
    9.17 μM
    Compound: Sorafenib
    Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    A-431 IC50
    0.12 μM
    Compound: Sorafenib
    Antiproliferative activity against human A431 cells
    Antiproliferative activity against human A431 cells
    		[PMID: 30503935]
    A-431 IC50
    10.46 μM
    Compound: Sorafenib
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    A-431 IC50
    3.32 μM
    Compound: Sorafenib
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    A2058 IC50
    3.8 μM
    Compound: sorafenib
    Cytotoxicity against human A2058 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2058 cells after 48 hrs by MTT assay
    		[PMID: 22708987]
    A375P IC50
    5.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375P cells
    Antiproliferative activity against human A375P cells
    		[PMID: 31926469]
    A375P IC50
    95 nM
    Compound: Sorafenib
    Cytotoxicity against human A375P cells
    Cytotoxicity against human A375P cells
    		[PMID: 31923860]
    A498 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human A498 cells after 48 hrs by SRB method
    Cytotoxicity against human A498 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    A498 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    A498 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    A498 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    A498 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    A498 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    A549 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    A549 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    A549 GI50
    4.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    A549 IC50
    0.08 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells
    Antiproliferative activity against human A549 cells
    		[PMID: 30503935]
    A549 IC50
    0.63 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25982075]
    A549 IC50
    0.75 μM
    Compound: Sorafenib
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    A549 IC50
    1.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 33129590]
    A549 IC50
    1.45 μM
    Compound: BAY-43-9006
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    		[PMID: 26342134]
    A549 IC50
    1.92 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    A549 IC50
    10.7 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    A549 IC50
    11.24 mM
    Compound: Sorafenib
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    A549 IC50
    12.54 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    A549 IC50
    13.64 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 26560049]
    A549 IC50
    180 nM
    Compound: Sorafenib
    Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method
    Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method
    		[PMID: 30826508]
    A549 IC50
    19.3 μM
    Compound: Sorafenib
    Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay
    		[PMID: 30108994]
    A549 IC50
    19.54 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    A549 IC50
    2.02 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26753815]
    A549 IC50
    2.9 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    A549 IC50
    2.92 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    A549 IC50
    2.92 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    A549 IC50
    25.671 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    A549 IC50
    27 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 30502686]
    A549 IC50
    27 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    A549 IC50
    27.71 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    A549 IC50
    3.1 μM
    Compound: Sorafenib
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    A549 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    A549 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    A549 IC50
    3.19 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    A549 IC50
    3.36 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    A549 IC50
    3.779 μg/mL
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay
    		[PMID: 29395969]
    A549 IC50
    3.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    A549 IC50
    4 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    A549 IC50
    4.47 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    A549 IC50
    4.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 23260578]
    A549 IC50
    5 μM
    Compound: 1
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34634618]
    A549 IC50
    5.13 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    A549 IC50
    5.21 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    		[PMID: 20181414]
    A549 IC50
    5.231 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		10.1039/C2MD20275A
    A549 IC50
    5.53 μM
    Compound: Sorafenib
    Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method
    Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method
    		[PMID: 30826508]
    A549 IC50
    5.62 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 32663641]
    A549 IC50
    6.08 μM
    Compound: Sorafenib
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0398-y
    A549 IC50
    6.11 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    A549 IC50
    6.21 μM
    Compound: Sorafenib
    Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    A549 IC50
    6.53 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27043268]
    A549 IC50
    6.53 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28340913]
    A549 IC50
    6.7 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    A549 IC50
    6.83 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    A549 IC50
    64.9 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    A549 IC50
    7.43 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    A549 IC50
    7.46 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 38894896]
    A549 IC50
    7.62 μM
    Compound: C1
    Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    A549 IC50
    8.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    A549 IC50
    8.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 37216813]
    ACHN GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    ACHN GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    ACHN GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    ACHN GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human ACHN cells after 48 hrs by SRB method
    Cytotoxicity against human ACHN cells after 48 hrs by SRB method
    		[PMID: 26590508]
    ACHN IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    ACHN IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    ACHN IC50
    3.3 μM
    Compound: Sora
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    ACHN IC50
    3.4 μM
    Compound: Sorafenib
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    		[PMID: 29297688]
    ACHN IC50
    3.4 μM
    Compound: Sorafenib
    Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay
    		[PMID: 29517908]
    ACHN IC50
    3.5 μM
    Compound: Sorafenib
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    		[PMID: 29786436]
    B16 IC50
    9.29 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37453330]
    B16-BL6 IC50
    36.48 μM
    Compound: Sorafenib
    Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay
    		[PMID: 29631788]
    B16-F1 IC50
    4.9 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    		[PMID: 20056548]
    B16-F1 IC50
    4.9 μM
    Compound: sorafenib
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    		[PMID: 18477505]
    BCPAP IC50
    6.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay
    Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    BEAS-2B IC50
    31.6 μM
    Compound: Sorafenib
    Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38354306]
    BGC-823 IC50
    10.91 μM
    Compound: Sorafenib
    Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 22721924]
    BGC-823 IC50
    3 μM
    Compound: Sorafenib
    Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    BMDM IC50
    164 nM
    Compound: Sorafenib
    Inhibition of CSF-1-induced C57BL6 mouse BMDM cell growth preincubated for 1 hr followed by CSF-1 addition and measured after 5 hrs by alamar blue assay
    Inhibition of CSF-1-induced C57BL6 mouse BMDM cell growth preincubated for 1 hr followed by CSF-1 addition and measured after 5 hrs by alamar blue assay
    		[PMID: 38850857]
    BT-549 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human BT549 cells after 48 hrs by SRB method
    Cytotoxicity against human BT549 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    BT-549 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    BT-549 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    BT-549 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    BT-549 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    BT-549 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    BXPC-3 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    BaF3 GI50
    0.23 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 GI50
    1.1 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 GI50
    1.28 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 GI50
    1.8 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 GI50
    1542 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    2.8 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    206.2 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    2637 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    5417 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    56.5 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    6.36 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 IC50
    0.006 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    0.012 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.013 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.014 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.078 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    1.015 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    1.112 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    1.348 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    1.454 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    2.458 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    2.804 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    3.681 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    4.208 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    5.82 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    7.4 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    7.997 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    > 10 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    Bel-7402 IC50
    10.26 μM
    Compound: sorafenib
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    Bel-7402 IC50
    10.31 μM
    Compound: Sorafenib
    Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay
    Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    Bel-7402 IC50
    10.87 μM
    Compound: Cpd S
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32827851]
    Bel-7402 IC50
    4.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    Bel-7402 IC50
    5.8 μM
    Compound: Sorafenib
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    Bel-7402 IC50
    6.03 μM
    Compound: Sorafenib
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    Bel7402/5-FU IC50
    13.31 μM
    Compound: Sorafenib
    Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    C6 IC50
    8.17 μM
    Compound: Sorafenib
    Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    CAKI-1 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB method
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition
    Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    CAKI-1 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    CAKI-1 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    CAKI-2 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    CCRF-CEM GI50
    2 μM
    Compound: 1
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method
    		[PMID: 26590508]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition
    Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition
    		[PMID: 38850857]
    CCRF-CEM IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    CCRF-CEM IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    COLO 205 GI50
    1.99 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO 205 cells assessed as reduction in cell growth
    Antiproliferative activity against human COLO 205 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    COLO 205 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB method
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition
    Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    COLO 205 IC50
    0.87 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    COLO 205 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    COLO 205 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    COLO 205 IC50
    7.04 μM
    Compound: Sorafenib
    Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    COLO 205 IC50
    > 3 μM
    Compound: Sorafenib
    Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    CT26 GI50
    14.7 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    CT26 GI50
    30.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    CT26 IC50
    2.1 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    Caco-2 IC50
    1.3 μM
    Compound: Sorafenib
    Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38354306]
    DU-145 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    DU-145 IC50
    24.91 μM
    Compound: Sorafenib
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    DU-145 IC50
    24.91 μM
    Compound: Sorafenib
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability
    Cytotoxicity against human DU-145 cells assessed as reduction in cell viability
    		[PMID: 33316752]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    DU-145 IC50
    5.1 μM
    Compound: sorafenib
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 22708987]
    DU-145 IC50
    83.736 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    EA.hy 926 IC50
    11.02 μM
    Compound: Sorafenib
    Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36508995]
    EA.hy 926 IC50
    11.74 μM
    Compound: Sorafenib
    Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay
    Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay
    		[PMID: 30503935]
    EA.hy 926 IC50
    11.74 μM
    Compound: Sorafenib
    Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 30616052]
    EA.hy 926 IC50
    18.52 μM
    Compound: Sorafenib
    Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay
    Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay
    		[PMID: 29032031]
    EA.hy 926 IC50
    24.36 μM
    Compound: Sorafenib
    Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay
    Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay
    		[PMID: 28068599]
    EA.hy 926 IC50
    24.36 μM
    Compound: Sorafenib
    Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay
    Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay
    		[PMID: 29102175]
    EJ IC50
    22.9 μM
    Compound: Sorafenib
    Cytotoxicity against human EJ cells after 48 hrs by MTT assay
    Cytotoxicity against human EJ cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    EKVX GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    EKVX GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    EKVX GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    EKVX IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    EOL1 IC50
    2.3 nM
    Compound: 4
    Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay
    Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay
    		10.1039/C1MD00175B
    Fibroblast IC50
    15.1 μM
    Compound: Sorafenib
    Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
    Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
    		[PMID: 20056548]
    Fibroblast IC50
    15.1 μM
    Compound: sorafenib
    Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay
    Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay
    		[PMID: 18477505]
    Fibroblast IC50
    15.1 μM
    Compound: sorafenib, velcade
    Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay
    Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay
    		[PMID: 17561392]
    GES1 GI50
    15.9 μM
    Compound: Sorafenib
    Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    GES1 GI50
    28.9 μM
    Compound: Sorafenib
    Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    GES1 IC50
    10.68 μM
    Compound: Sorafenib
    Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27162123]
    GES1 IC50
    15.8 μM
    Compound: Sorafenib
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    		[PMID: 23871909]
    GES1 IC50
    9.47 μM
    Compound: Sorafenib
    Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    GES1 IC50
    9.59 μM
    Compound: Sorafenib
    Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33493829]
    H22 IC50
    10.72 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
    Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
    		[PMID: 38224754]
    HCC 2998 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HCC 2998 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HCC 2998 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HCC 2998 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HCC 2998 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    HCC 2998 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HCCLM3 IC50
    6.3 μM
    Compound: Sora
    Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 38905539]
    HCCLM9 IC50
    21.07 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HCCLM9 IC50
    3.15 μM
    Compound: sorafenib
    Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    HCCLM9 IC50
    9.21 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 37182331]
    HCT-116 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB method
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    HCT-116 GI50
    19.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    HCT-116 GI50
    5.4 μM
    Compound: BAY-439006
    Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay
    Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay
    		[PMID: 15225706]
    HCT-116 GI50
    5.42 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34147745]
    HCT-116 GI50
    6.6 μM
    Compound: BAY-439006
    Ability of compound to inhibit anchorage independent colony formation (soft agar growth assay) in HCT116 cells
    Ability of compound to inhibit anchorage independent colony formation (soft agar growth assay) in HCT116 cells
    		[PMID: 15225706]
    HCT-116 GI50
    9 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    HCT-116 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HCT-116 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HCT-116 IC50
    10.55 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37453330]
    HCT-116 IC50
    16.12 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HCT-116 IC50
    168 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    HCT-116 IC50
    2 μM
    Compound: 1
    Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant
    Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant
    		[PMID: 22808911]
    HCT-116 IC50
    2.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 23260578]
    HCT-116 IC50
    23.31 μM
    Compound: Sorafenib
    Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 29602674]
    HCT-116 IC50
    5.47 μM
    Compound: SOR
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HCT-116 IC50
    5.65 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 24215818]
    HCT-116 IC50
    6.82 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
    		[PMID: 37453330]
    HCT-116 IC50
    7.75 μM
    Compound: Sorafenib
    Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0400-8
    HCT-116 IC50
    7.8 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22483592]
    HCT-116 IC50
    8.08 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 24440479]
    HCT-116 IC50
    8.08 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    HCT-116 IC50
    8.41 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells by MTT assay
    Antiproliferative activity against human HCT116 cells by MTT assay
    		10.1039/C4MD00536H
    HCT-116 IC50
    8.41 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 29631788]
    HCT-116 IC50
    9.4 μM
    Compound: 1; BAY-43-9006
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    HCT-15 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB method
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell growth
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition
    Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    HCT-15 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HCT-15 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HEK-293T IC50
    6.38 μM
    Compound: Sorafenib
    Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    HEK293 IC50
    0.12 μM
    Compound: Sorafenib
    Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP
    Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP
    		[PMID: 26318998]
    HEK293 IC50
    2.95 μM
    Compound: Sorafenib
    Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 35635929]
    HEK293 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against HEK293 cells by MTT assay
    Antiproliferative activity against HEK293 cells by MTT assay
    		[PMID: 30502686]
    HEK293 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay
    Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HGC-27 IC50
    5.15 μM
    Compound: Sorafenib
    Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    HGC-27 IC50
    5.22 μM
    Compound: Sorafenib
    Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    HGC-27 IC50
    > 150 μM
    Compound: Sorafenib
    Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HK-2 IC50
    2.6 μM
    Compound: Sora
    Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    HL-60 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HL-60 IC50
    0.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 35148084]
    HL-60 IC50
    1.68 μM
    Compound: Nexavar, Sorafenib
    Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay
    		[PMID: 24858546]
    HL-60 IC50
    2.59 μM
    Compound: Sorafenib
    Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
    		[PMID: 30108964]
    HL-60 IC50
    2.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HL-60 IC50
    3.14 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HL-60 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL60 cells by MTT assay
    Antiproliferative activity against human HL60 cells by MTT assay
    		[PMID: 30502686]
    HL-60(TB) GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method
    Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HL-60(TB) GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HL-60(TB) GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HL-60(TB) IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HL-60(TB) IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    HL-60(TB) IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HMEC-1 IC50
    34 μM
    Compound: Sorafenib
    Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay
    Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay
    		[PMID: 30502686]
    HMEC-1 IC50
    34 μM
    Compound: Sorafenib
    Antiproliferative activity against HMEC1 cells by MTT assay
    Antiproliferative activity against HMEC1 cells by MTT assay
    		[PMID: 30502686]
    HMEC-1 IC50
    34 μM
    Compound: Sorafenib
    Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay
    Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HOP-62 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB method
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HOP-62 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HOP-62 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HOP-62 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HOP-62 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HOP-62 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP-92 cells assessed as reduction in cell growth
    Antiproliferative activity against human HOP-92 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HOP-92 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HOP-92 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HOS-TE85 IC50
    4.814 μM
    Compound: Sorafenib
    Antiproliferative activity against human MNNG/HOS cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human MNNG/HOS cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 38232462]
    HS27 GI50
    7.85 μM
    Compound: Sorafenib
    Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay
    Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 21353571]
    HS27 GI50
    > 30 μM
    Compound: Sorafenib
    Cytotoxicity against human HS27 cells after 24 hrs by MTT assay
    Cytotoxicity against human HS27 cells after 24 hrs by MTT assay
    		[PMID: 26318067]
    HS27 IC50
    7.8 μM
    Compound: Sorafenib
    Cytotoxicity against human HS27 cells by MTT assay
    Cytotoxicity against human HS27 cells by MTT assay
    		[PMID: 19897366]
    HS27 IC50
    7.8 μM
    Compound: Sorafenib
    Cytotoxicity against human HS27 cells
    Cytotoxicity against human HS27 cells
    		[PMID: 31923860]
    HS27 IC50
    7.8 μM
    Compound: sorafenib
    Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay
    		[PMID: 19857963]
    HS27 IC50
    7.85 μM
    Compound: Sorafenib
    Antiproliferative activity against human HS27 cells
    Antiproliferative activity against human HS27 cells
    		[PMID: 19464887]
    HS27 IC50
    8.3 μM
    Compound: Sorafenib
    Cytotoxicity against human HS27 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HS27 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    		[PMID: 38850857]
    HT-1080 IC50
    < 10 μM
    Compound: 1; BAY 43-9006
    Antitumor activity against human HT-1080 cells assessed as inhibition of cell viability
    Antitumor activity against human HT-1080 cells assessed as inhibition of cell viability
    		[PMID: 36332549]
    HT-29 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    HT-29 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB method
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    HT-29 GI50
    25.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    HT-29 GI50
    25.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    HT-29 IC50
    0.39 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    HT-29 IC50
    10 μM
    Compound: Sorafenib
    Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    HT-29 IC50
    10.05 mM
    Compound: Sorafenib
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    HT-29 IC50
    11.51 μM
    Compound: 14
    Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis
    Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis
    		[PMID: 36346971]
    HT-29 IC50
    15.2 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    HT-29 IC50
    17 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells by MTT assay
    Antiproliferative activity against human HT-29 cells by MTT assay
    		[PMID: 30502686]
    HT-29 IC50
    17 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HT-29 IC50
    17.28 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 32663641]
    HT-29 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HT-29 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HT-29 IC50
    2.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HT-29 IC50
    2.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    		[PMID: 29886324]
    HT-29 IC50
    3.27 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HT-29 IC50
    3.37 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    HT-29 IC50
    3.56 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38422700]
    HT-29 IC50
    3.61 μM
    Compound: 1
    Antiproliferative activity against human HT-29 cells
    Antiproliferative activity against human HT-29 cells
    		[PMID: 30216849]
    HT-29 IC50
    3.61 μM
    Compound: 5
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    HT-29 IC50
    3.61 μM
    Compound: 5
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    HT-29 IC50
    3.61 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    HT-29 IC50
    3.97 μM
    Compound: Sorafenib
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    HT-29 IC50
    4 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    HT-29 IC50
    5.29 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    HT-29 IC50
    5.57 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    HT-29 IC50
    5.9 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    HT-29 IC50
    6.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    HT-29 IC50
    8.44 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    		[PMID: 29602674]
    HT-29 IC50
    > 150 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HUVEC EC50
    718 nM
    Compound: Sorafenib
    Antiangiogenic activity in HUVEC after 72 hrs by MTT assay
    Antiangiogenic activity in HUVEC after 72 hrs by MTT assay
    		[PMID: 27010810]
    HUVEC GI50
    6 μM
    Compound: BAY 43-9006, Nexavar
    Antiproliferative activity against HUVEC after 72 hrs by MTT assay
    Antiproliferative activity against HUVEC after 72 hrs by MTT assay
    		[PMID: 23726028]
    HUVEC IC50
    0.59 nM
    Compound: sorafenib
    Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy
    Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy
    		[PMID: 18849971]
    HUVEC IC50
    1.49 μM
    Compound: Sorafenib
    Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay
    Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay
    		[PMID: 29189002]
    HUVEC IC50
    18.24 μM
    Compound: Sorafenib
    Cytotoxicity against HUVEC cells assessed as reduction in cell viability and measured after 24 hrs by MTT assay
    Cytotoxicity against HUVEC cells assessed as reduction in cell viability and measured after 24 hrs by MTT assay
    		[PMID: 37484562]
    HUVEC IC50
    2.69 μM
    Compound: Sorafenib
    Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay
    Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay
    		[PMID: 29886324]
    HUVEC IC50
    2.8 μM
    Compound: Sorafenib
    Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay
    Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    HUVEC IC50
    4 μM
    Compound: sorafenib
    Cytotoxicity against HUVEC by MTT assay
    Cytotoxicity against HUVEC by MTT assay
    		[PMID: 23562241]
    HUVEC IC50
    4.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    HUVEC IC50
    40.6 μM
    Compound: Sorafenib
    Cytotoxicity against HUVEC after 48 hrs by MTT assay
    Cytotoxicity against HUVEC after 48 hrs by MTT assay
    		[PMID: 28342400]
    HUVEC IC50
    5.35 μM
    Compound: C1
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    HUVEC IC50
    6.42 μM
    Compound: Sorafenib
    Antiproliferative activity against HUVEC after 48 hrs by MTT assay
    Antiproliferative activity against HUVEC after 48 hrs by MTT assay
    		[PMID: 24440479]
    HUVEC IC50
    6.42 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    HUVEC IC50
    73.16 μM
    Compound: Sorafenib
    Anti-angiogenesis activity in HUVEC cells
    Anti-angiogenesis activity in HUVEC cells
    		[PMID: 37484562]
    HUVEC IC50
    8.33 μM
    Compound: Sorafenib
    Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33493829]
    HUVEC IC50
    89.77 μM
    Compound: Sorafenib
    Cytotoxicity against HUVECs incubated for 72 hrs by MTT assay
    Cytotoxicity against HUVECs incubated for 72 hrs by MTT assay
    		[PMID: 38894896]
    HUVEC IC50
    9.66 μM
    Compound: Sorafenib
    Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    HeLa IC50
    0.27 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells
    Antiproliferative activity against human HeLa cells
    		[PMID: 30503935]
    HeLa IC50
    0.64 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 30015070]
    HeLa IC50
    10.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38422700]
    HeLa IC50
    12.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29103873]
    HeLa IC50
    2.44 μM
    Compound: Sorafenib
    Growth inhibition of human HeLa cells after 48 hrs by MTT assay
    Growth inhibition of human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    HeLa IC50
    3.3 μM
    Compound: BAY-439006
    Inhibition of EGF-stimulated Elk1-luciferase reporter assay in HeLa cells
    Inhibition of EGF-stimulated Elk1-luciferase reporter assay in HeLa cells
    		[PMID: 15225706]
    HeLa IC50
    3.31 μM
    Compound: SFN
    Cytotoxicity against human HeLa cells by SRB assay
    Cytotoxicity against human HeLa cells by SRB assay
    		[PMID: 36067930]
    HeLa IC50
    4.163 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23362959]
    HeLa IC50
    4.59 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
    		[PMID: 30108964]
    HeLa IC50
    5.23 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26342867]
    HeLa IC50
    6.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 30502686]
    HeLa IC50
    6.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HeLa IC50
    7.68 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    HeLa IC50
    8.04 μM
    Compound: SOR
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HeLa IC50
    8.74 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    Hep 3B2 IC50
    11.2 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 28342400]
    Hep 3B2 IC50
    12.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    		[PMID: 36461923]
    Hep 3B2 IC50
    14.08 μM
    Compound: sorafenib
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    Hep 3B2 IC50
    2.63 μM
    Compound: Sorafenib
    Growth inhibition of human Hep3B cells after 48 hrs by MTT assay
    Growth inhibition of human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    Hep 3B2 IC50
    4.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells measured by MTT assay
    Antiproliferative activity against human Hep3B cells measured by MTT assay
    		[PMID: 35764033]
    Hep 3B2 IC50
    4.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 38850857]
    Hep 3B2 IC50
    4.33 μM
    Compound: Sor
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Hep 3B2 IC50
    5.2 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay
    Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32371334]
    Hep 3B2 IC50
    5.2 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36223633]
    Hep 3B2 IC50
    5.49 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    Hep 3B2 IC50
    7.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36745506]
    Hep 3B2 IC50
    8.55 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 36549116]
    Hep 3B2 IC50
    8.62 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    Hep 3B2 IC50
    9.4 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    Hep 3B2 IC50
    < 10 μM
    Compound: 1; BAY 43-9006
    Antitumor activity against human Hep3B cells assessed as inhibition of cell viability
    Antitumor activity against human Hep3B cells assessed as inhibition of cell viability
    		[PMID: 36332549]
    HepG2 EC50
    302 nM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    HepG2 GI50
    2.5 μM
    Compound: 3
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay
    		[PMID: 32272419]
    HepG2 GI50
    4.5 μM
    Compound: BAY 43-9006, Nexavar
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 23726028]
    HepG2 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    HepG2 IC50
    1.06 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 29628325]
    HepG2 IC50
    10.48 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		10.1039/C4MD00536H
    HepG2 IC50
    11.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38422700]
    HepG2 IC50
    11.49 μM
    Compound: sorafenib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    HepG2 IC50
    12 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    		[PMID: 27422336]
    HepG2 IC50
    12.33 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    		[PMID: 38784474]
    HepG2 IC50
    12.4 μg/mL
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 29103873]
    HepG2 IC50
    12.54 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    HepG2 IC50
    12.669 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		10.1039/C2MD20275A
    HepG2 IC50
    12.8 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs
    Anti-hepatoma activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs
    		[PMID: 38521176]
    HepG2 IC50
    14 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 38536967]
    HepG2 IC50
    15 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29103873]
    HepG2 IC50
    16.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay
    		[PMID: 30114660]
    HepG2 IC50
    16.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    		[PMID: 36461923]
    HepG2 IC50
    19.33 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
    		[PMID: 37453330]
    HepG2 IC50
    2.1 μM
    Compound: sorafenib
    Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    HepG2 IC50
    2.17 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    		[PMID: 34479065]
    HepG2 IC50
    2.41 μM
    Compound: C1
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    HepG2 IC50
    2.69 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36508995]
    HepG2 IC50
    2.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    HepG2 IC50
    2.84 μM
    Compound: Sorafenib
    Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    HepG2 IC50
    2.86 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells measured by MTT assay
    Antiproliferative activity against human HepG2 cells measured by MTT assay
    		[PMID: 35764033]
    HepG2 IC50
    2.86 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 38850857]
    HepG2 IC50
    29 μM
    Compound: Sorafenib
    Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay
    		[PMID: 30108994]
    HepG2 IC50
    29.35 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HepG2 IC50
    29.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    HepG2 IC50
    3.04 μM
    Compound: 1
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    HepG2 IC50
    3.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT based colorimetric analysis
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT based colorimetric analysis
    		[PMID: 37453330]
    HepG2 IC50
    3.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    HepG2 IC50
    3.4 μM
    Compound: Sorafenib
    Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
    Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
    		[PMID: 26071861]
    HepG2 IC50
    3.44 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    HepG2 IC50
    3.44 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    HepG2 IC50
    3.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 25462265]
    HepG2 IC50
    3.5 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells by sulforhodamine B assay
    		[PMID: 31401008]
    HepG2 IC50
    3.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    HepG2 IC50
    3.66 μM
    Compound: Sor
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    HepG2 IC50
    4 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    HepG2 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 23260578]
    HepG2 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23932071]
    HepG2 IC50
    5.06 μM
    Compound: 1
    Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36270111]
    HepG2 IC50
    5.06 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    HepG2 IC50
    5.2 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31926469]
    HepG2 IC50
    5.23 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    HepG2 IC50
    5.5 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 32323991]
    HepG2 IC50
    5.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36745506]
    HepG2 IC50
    5.74 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461318]
    HepG2 IC50
    5.78 μM
    Compound: Sorafenib
    Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    HepG2 IC50
    6.18 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    HepG2 IC50
    6.2 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    HepG2 IC50
    6.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23932071]
    HepG2 IC50
    6.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		[PMID: 34128674]
    HepG2 IC50
    6.422 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 36549116]
    HepG2 IC50
    6.5 μM
    Compound: 1
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay
    		[PMID: 33460739]
    HepG2 IC50
    6.54 μM
    Compound: SFN
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 36067930]
    HepG2 IC50
    6.7 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    HepG2 IC50
    6.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells
    Antiproliferative activity against human HepG2 cells
    		[PMID: 33421712]
    HepG2 IC50
    7.22 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    HepG2 IC50
    7.31 μM
    Compound: 1; BAY-43-9006
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    HepG2 IC50
    7.67 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32791397]
    HepG2 IC50
    7.839 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    HepG2 IC50
    8 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32842729]
    HepG2 IC50
    8.27 μM
    Compound: 1
    Antiproliferative activity against human HepG2 cells
    Antiproliferative activity against human HepG2 cells
    		[PMID: 30216849]
    HepG2 IC50
    8.42 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    HepG2 IC50
    8.42 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    HepG2 IC50
    8.67 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    HepG2 IC50
    9.03 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 37182331]
    HepG2 IC50
    9.14 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		[PMID: 26560049]
    HepG2 IC50
    9.18 μM
    Compound: SOR
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HepG2 IC50
    9.64 mM
    Compound: Sorafenib
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    HepG2 IC50
    9.7 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36223633]
    HepG2 IC50
    9.75 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32371334]
    HepG2 IC50
    < 10 μM
    Compound: 1; BAY 43-9006
    Antitumor activity against human HepG2 cells assessed as inhibition of cell viability
    Antitumor activity against human HepG2 cells assessed as inhibition of cell viability
    		[PMID: 36332549]
    Hepatocyte IC50
    16.55 μM
    Compound: Sorafenib
    Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay
    Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay
    		[PMID: 34479065]
    Hs-578T GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB method
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB method
    		[PMID: 26590508]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition
    Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition
    		[PMID: 38850857]
    Hs-578T IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    Hs-578T IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    Huh-7 GI50
    4 μM
    Compound: BAY 43-9006, Nexavar
    Cytotoxicity against human HuH7 cells by MTT assay
    Cytotoxicity against human HuH7 cells by MTT assay
    		[PMID: 23726028]
    Huh-7 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    Huh-7 IC50
    10.1 μM
    Compound: Sorafenib
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32842729]
    Huh-7 IC50
    10.94 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    Huh-7 IC50
    11.3 μM
    Compound: Sorafenib
    Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    		[PMID: 27422336]
    Huh-7 IC50
    14.66 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
    		[PMID: 38224754]
    Huh-7 IC50
    2.6 μM
    Compound: sorafenib
    Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    Huh-7 IC50
    2.68 μM
    Compound: Sor
    Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Huh-7 IC50
    4.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells by MTT assay
    Antiproliferative activity against human Huh-7 cells by MTT assay
    		[PMID: 34128674]
    Huh-7 IC50
    7.1 μM
    Compound: Sorafenib
    Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    Huh-7 IC50
    7.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells
    Antiproliferative activity against human Huh-7 cells
    		[PMID: 33421712]
    Huh-7 IC50
    7.55 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    Huh-7 IC50
    7.92 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32791397]
    Huh-7 IC50
    8.8 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs
    Anti-hepatoma activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs
    		[PMID: 38521176]
    Huh-7 IC50
    9.48 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 37182331]
    Huh-7 IC50
    9.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    		[PMID: 36461923]
    Huh-7 IC50
    < 10 μM
    Compound: 1; BAY 43-9006
    Antitumor activity against human Huh-7 cells assessed as inhibition of cell viability
    Antitumor activity against human Huh-7 cells assessed as inhibition of cell viability
    		[PMID: 36332549]
    Huh-7.5 CC50
    > 20 μM
    Compound: 25
    Cytotoxicity against human Huh7.5 cells
    Cytotoxicity against human Huh7.5 cells
    		[PMID: 33539089]
    IGROV-1 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method
    Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    IGROV-1 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    IGROV-1 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    IGROV-1 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    IGROV-1 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    IGROV-1 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    JeKo-1 IC50
    1070 nM
    Compound: 12; Sor
    Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 36399923]
    Jurkat IC50
    14.37 μM
    Compound: 14
    Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis
    Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis
    		[PMID: 36346971]
    K562 GI50
    0.612 μM
    Compound: 3
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay
    		[PMID: 32272419]
    K562 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human K562 cells after 48 hrs by SRB method
    Cytotoxicity against human K562 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as reduction in cell growth
    Antiproliferative activity against human K562 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    K562 GI50
    6.2 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method
    Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method
    		[PMID: 21708468]
    K562 GI50
    7.3 μM
    Compound: 2
    Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    K562 GI50
    7.3 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay
    Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay
    		[PMID: 23618709]
    K562 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    K562 IC50
    0.86 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    K562 IC50
    0.86 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    K562 IC50
    1.22 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    K562 IC50
    13.85 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    K562 IC50
    17.23 μM
    Compound: 1
    Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    K562 IC50
    2.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    K562 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    K562 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    K562 IC50
    5.08 μM
    Compound: Sor
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    K562 IC50
    7740 nM
    Compound: 12; Sor
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 36399923]
    KB GI50
    5.43 μM
    Compound: Sorafenib
    Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    KETR3 IC50
    18.8 μM
    Compound: Sorafenib
    Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    KETR3 IC50
    8.27 μM
    Compound: 1
    Antiproliferative activity against human Ketr3 cells
    Antiproliferative activity against human Ketr3 cells
    		[PMID: 30216849]
    KM12 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human KM12 cells after 48 hrs by SRB method
    Cytotoxicity against human KM12 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    KM12 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    KM12 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    KM12 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    KM12 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    KM12 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    Kasumi 1 IC50
    0.015 μM
    Compound: 2
    Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    L02 IC50
    5.98 μM
    Compound: sorafenib
    Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    L02 IC50
    52.87 μM
    Compound: Sorafenib
    Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    L02 IC50
    72.9 μM
    Compound: Sorafenib
    Cytotoxicity against human LO2 cells
    Cytotoxicity against human LO2 cells
    		[PMID: 31668972]
    L02 IC50
    9.1 μM
    Compound: Sorafenib
    Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
    		[PMID: 32323991]
    LC-2-ad GI50
    3224.13 nM
    Compound: Sorafenib
    Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay
    Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay
    		[PMID: 35081714]
    LOX IMVI GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method
    		[PMID: 26590508]
    LOX IMVI GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    LOX IMVI GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    LOX IMVI GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    LOX IMVI IC50
    4.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    LoVo IC50
    0.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells
    Antiproliferative activity against human LoVo cells
    		[PMID: 30503935]
    LoVo IC50
    14.57 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    LoVo IC50
    2.52 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    LoVo IC50
    3.3 μM
    Compound: Sorafenib
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    LoVo IC50
    6.56 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    LoVo IC50
    6.56 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    LoVo IC50
    9.47 μM
    Compound: Sorafenib
    Growth inhibition of human LoVo cells after 48 hrs by MTT assay
    Growth inhibition of human LoVo cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    M14 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human M14 cells after 48 hrs by SRB method
    Cytotoxicity against human M14 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human M14 cells assessed as cell growth inhibition
    Antiproliferative activity against human M14 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    M14 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    M14 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MCF7 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    MCF7 GI50
    4.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    MCF7 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    MCF7 IC50
    0.09 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 30503935]
    MCF7 IC50
    0.19 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25496804]
    MCF7 IC50
    0.78 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    MCF7 IC50
    1.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25637123]
    MCF7 IC50
    10.87 mM
    Compound: Sorafenib
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    MCF7 IC50
    11.34 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    MCF7 IC50
    11.34 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    MCF7 IC50
    14 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 30502686]
    MCF7 IC50
    14 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    MCF7 IC50
    15 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay
    		[PMID: 33460739]
    MCF7 IC50
    17.87 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 37453330]
    MCF7 IC50
    2.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    MCF7 IC50
    2.51 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 30216849]
    MCF7 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MCF7 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MCF7 IC50
    2.78 μM
    Compound: Sorafenib
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    MCF7 IC50
    3.07 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
    		[PMID: 30108964]
    MCF7 IC50
    3.18 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    MCF7 IC50
    3.18 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    MCF7 IC50
    3.47 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    MCF7 IC50
    3.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    		[PMID: 34479065]
    MCF7 IC50
    3.64 μM
    Compound: Sorafenib
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    MCF7 IC50
    38.168 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    MCF7 IC50
    4.21 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27043268]
    MCF7 IC50
    4.21 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28340913]
    MCF7 IC50
    4.27 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    MCF7 IC50
    4.33 μM
    Compound: I; BAY 43-9006
    Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay
    		[PMID: 31284081]
    MCF7 IC50
    4.33 μg/mL
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 28505536]
    MCF7 IC50
    4.88 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 38894896]
    MCF7 IC50
    43.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    5.1 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 38283214]
    MCF7 IC50
    5.5 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    MCF7 IC50
    5.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 33421712]
    MCF7 IC50
    5.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    MCF7 IC50
    7.21 μM
    Compound: 1; BAY-43-9006
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    MCF7 IC50
    7.26 μM
    Compound: SOR
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    MCF7 IC50
    7.33 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    MCF7 IC50
    8.83 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    MCF7 IC50
    9.12 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    MCF7 IC50
    9.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38422700]
    MDA-MB-231 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    MDA-MB-231 GI50
    1.26 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    MDA-MB-231 GI50
    4.13 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    MDA-MB-231 IC50
    0.94 μM
    Compound: 5
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    MDA-MB-231 IC50
    0.94 μM
    Compound: 5
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    MDA-MB-231 IC50
    1.26 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MDA-MB-231 IC50
    1.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MDA-MB-231 IC50
    11.84 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    MDA-MB-231 IC50
    14.62 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 24440479]
    MDA-MB-231 IC50
    14.62 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    MDA-MB-231 IC50
    15.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    MDA-MB-231 IC50
    17.38 μM
    Compound: C1
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    MDA-MB-231 IC50
    17.84 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    		10.1039/C4MD00536H
    MDA-MB-231 IC50
    2 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    MDA-MB-231 IC50
    2.5 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells
    Cytotoxicity against human MDA-MB-231 cells
    		[PMID: 22414612]
    MDA-MB-231 IC50
    2.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29202403]
    MDA-MB-231 IC50
    3.08 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    MDA-MB-231 IC50
    3.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    MDA-MB-231 IC50
    35 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    MDA-MB-231 IC50
    35 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    MDA-MB-231 IC50
    36 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 22483592]
    MDA-MB-231 IC50
    36.6 μM
    Compound: Sorafenib
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0400-8
    MDA-MB-231 IC50
    4.77 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    MDA-MB-231 IC50
    5.1 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    MDA-MB-231 IC50
    5.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells
    Antiproliferative activity against human MDA-MB-231 cells
    		[PMID: 33421712]
    MDA-MB-231 IC50
    7.18 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 22721924]
    MDA-MB-231 IC50
    7.62 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    		[PMID: 20181414]
    MDA-MB-231 IC50
    8.52 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34536673]
    MDA-MB-435 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition
    Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    MDA-MB-435 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MDA-MB-435 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MDA-MB-435 IC50
    1.67 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    MDA-MB-435 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    MDA-MB-435 IC50
    2.11 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay
    Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 29189002]
    MDA-MB-436 IC50
    4.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29202403]
    MDA-MB-468 GI50
    1.99 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    MDA-MB-468 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MDA-MB-468 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MDA-MB-468 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MDA-MB-468 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MDA-MB-468 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    MDA-MB-468 IC50
    12.17 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    MDA-MB-468 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MDA-MB-468 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    MDA-MB-468 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MDA-MB-468 IC50
    4.9 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    MDA-MB-468 IC50
    4.9 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells
    Antiproliferative activity against human MDA-MB-468 cells
    		[PMID: 33421712]
    MDA-MB-468 IC50
    7.31 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 35635929]
    MGC-803 IC50
    19.92 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 29103873]
    MGC-803 IC50
    50.78 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    MGC-803 IC50
    7.99 μM
    Compound: Cpd S
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32827851]
    MGC-803 IC50
    7.99 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC803 cells by MTT assay
    Antiproliferative activity against human MGC803 cells by MTT assay
    		[PMID: 26560049]
    MGC-803 IC50
    9.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    MHCC97H IC50
    1.3 mg/kg
    Compound: Sorafenib
    In vivo antitumor activity against human MHCC97H cells xenografted in po dosed nude mouse assessed as reduction tumor volume
    In vivo antitumor activity against human MHCC97H cells xenografted in po dosed nude mouse assessed as reduction tumor volume
    		[PMID: 36503229]
    MHCC97H IC50
    15 μM
    Compound: Sorafenib
    Cytotoxicity against human MHCC97H cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human MHCC97H cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 38536967]
    MHCC97H IC50
    9.32 μM
    Compound: Sorafenib
    Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay
    Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    MIA PaCa-2 IC50
    9.32 μM
    Compound: Sorafenib
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    MKN-28 IC50
    17 μM
    Compound: Sorafenib
    Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    MKN-45 IC50
    2.32 μM
    Compound: 1
    Antiproliferative activity against human MKN45 cells
    Antiproliferative activity against human MKN45 cells
    		[PMID: 30216849]
    MKN-45 IC50
    2.32 μM
    Compound: 5
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    MKN-45 IC50
    2.32 μM
    Compound: 5
    Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    MKN-45 IC50
    2.32 μM
    Compound: Sorafenib
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    MOLM-13 GI50
    0.008 μM
    Compound: Sorafenib
    Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
    Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
    		[PMID: 37535845]
    MOLM-13 GI50
    0.056 μM
    Compound: 2
    Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    MOLM-13 GI50
    0.056 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay
    Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay
    		[PMID: 23618709]
    MOLM-13 GI50
    0.056 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method
    Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method
    		[PMID: 21708468]
    MOLM-13 GI50
    0.934 μM
    Compound: Sorafenib
    Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
    Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
    		[PMID: 37535845]
    MOLM-13 GI50
    56 nM
    Compound: 2, BAY-439006
    Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant
    Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant
    		[PMID: 22726931]
    MOLM-13 IC50
    0.002 μM
    Compound: Sorafenib
    Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs
    Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs
    		[PMID: 24641103]
    MOLM-13 IC50
    0.005 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    MOLM-13 IC50
    8.7 nM
    Compound: Sorafenib
    Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    		[PMID: 35033885]
    MOLM-13 IC50
    > 3 μM
    Compound: Sorafenib
    Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    MOLM-13 IC50
    > 3 μM
    Compound: Sorafenib
    Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs
    Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs
    		[PMID: 24641103]
    MOLT-4 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method
    Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    MOLT-4 GI50
    9 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human MOLT4 after 72 hrs by MTS method
    Antiproliferation activity against human MOLT4 after 72 hrs by MTS method
    		[PMID: 21708468]
    MOLT-4 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    MOLT-4 IC50
    2502 nM
    Compound: 12; Sor
    Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 36399923]
    MOLT-4 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MOLT-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    MOLT-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MOLT-4 IC50
    5.94 μM
    Compound: Sor
    Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    MRC5 IC50
    11.1 μM
    Compound: 1
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36270111]
    MRC5 IC50
    24.11 μM
    Compound: Sorafenib
    Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    MV4-11 GI50
    0.0009 μM
    Compound: 3
    Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay
    Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay
    		[PMID: 32272419]
    MV4-11 GI50
    0.03 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method
    Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method
    		[PMID: 21708468]
    MV4-11 GI50
    0.043 μM
    Compound: 2
    Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    MV4-11 GI50
    0.043 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay
    Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay
    		[PMID: 23618709]
    MV4-11 IC50
    0.004 μM
    Compound: Sorafenib
    Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay
    Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 29357250]
    MV4-11 IC50
    0.007 μM
    Compound: Sorafenib
    Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 23362959]
    MV4-11 IC50
    0.007 μM
    Compound: Sorafenib
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26342867]
    MV4-11 IC50
    0.015 μM
    Compound: 2
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    MV4-11 IC50
    0.3 μM
    Compound: Sorafenib
    Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    MV4-11 IC50
    0.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    MV4-11 IC50
    0.51 μM
    Compound: 1
    Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    MV4-11 IC50
    0.87 nM
    Compound: 4
    Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay
    Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay
    		10.1039/C1MD00175B
    MV4-11 IC50
    0.87 nM
    Compound: BAY-439006, Sorafenib
    Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay
    		[PMID: 19754199]
    MV4-11 IC50
    0.87 nM
    Compound: Sorafenib
    Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay
    Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay
    		[PMID: 19654408]
    MV4-11 IC50
    1.59 nM
    Compound: Sorafenib
    Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    MV4-11 IC50
    4 nM
    Compound: 12; Sor
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 36399923]
    MV4-11 IC50
    7.7 nM
    Compound: Sorafenib
    Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    		[PMID: 35033885]
    MV4-11 IC50
    < 0.006 μM
    Compound: Sor
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay
    		[PMID: 29360358]
    MX1 IC50
    8.27 μM
    Compound: 1
    Antiproliferative activity against human MX1 cells
    Antiproliferative activity against human MX1 cells
    		[PMID: 30216849]
    MX1 IC50
    8.27 μM
    Compound: Sorafenib
    Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    Mahlavu IC50
    13.4 μM
    Compound: Sorafenib
    Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay
    Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay
    		[PMID: 36018000]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition
    Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition
    		[PMID: 38850857]
    Malme-3M IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    Malme-3M IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H1299 IC50
    3.4 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38354306]
    NCI-H1417 IC50
    5.84 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H146 IC50
    8.01 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H1650 IC50
    18.09 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H1975 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    		[PMID: 27010810]
    NCI-H1975 IC50
    9.27 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H211 IC50
    16.47 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H2170 IC50
    22.59 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H226 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H226 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H226 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H226 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H226 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H226 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H226 IC50
    7.92 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H23 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H23 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H23 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H23 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H23 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H23 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H23 IC50
    2.4 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38354306]
    NCI-H322M GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H322M GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H322M GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H322M GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H322M IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H322M IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    NCI-H322M IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H460 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    NCI-H460 IC50
    10.8 μM
    Compound: Sorafenib
    Cytotoxicity against human H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human H460 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    NCI-H460 IC50
    2.15 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    NCI-H460 IC50
    2.19 μM
    Compound: 1
    Antiproliferative activity against human NCI-H460 cells
    Antiproliferative activity against human NCI-H460 cells
    		[PMID: 30216849]
    NCI-H460 IC50
    2.19 μM
    Compound: 5
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    NCI-H460 IC50
    2.19 μM
    Compound: 5
    Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    NCI-H460 IC50
    2.19 μM
    Compound: Sorafenib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    NCI-H460 IC50
    2.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    NCI-H460 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H460 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H460 IC50
    3.68 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H460 IC50
    3.9 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    NCI-H520 IC50
    11.5 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H522 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H522 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H522 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H522 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H522 IC50
    19.26 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461318]
    NCI-H522 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H522 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H522 IC50
    5.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    NCI-H526 IC50
    14.68 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H82 IC50
    1.77 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method
    Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI/ADR-RES cells assessed as reduction in cell growth
    Antiproliferative activity against human NCI/ADR-RES cells assessed as reduction in cell growth
    		[PMID: 27155467]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI/ADR-RES IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI/ADR-RES IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NIH3T3 GI50
    0.32 μM
    Compound: Sorafenib
    Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
    Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    NIH3T3 GI50
    > 10 μM
    Compound: Sorafenib
    Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
    Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
    		[PMID: 29133048]
    NIH3T3 IC50
    24.75 μM
    Compound: Sorafenib, Nexavar
    Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum
    Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum
    		[PMID: 21592628]
    NIH3T3 IC50
    24.75 μM
    Compound: Sorafenib, Nexavar
    Antiproliferative activity against mouse NIH/3T3 cells
    Antiproliferative activity against mouse NIH/3T3 cells
    		[PMID: 22647720]
    Neutrophil IC50
    0.9 μg/mL
    Compound: Sorafenib
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
    		[PMID: 28218000]
    Neutrophil IC50
    1.27 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis
    		[PMID: 23647825]
    Neutrophil IC50
    1.5 μg/mL
    Compound: Sorafenib
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins by spectrophotometry
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins by spectrophotometry
    		[PMID: 28218000]
    Neutrophil IC50
    1.9 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry
    		[PMID: 25419616]
    Neutrophil IC50
    2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry
    		[PMID: 24388689]
    Neutrophil IC50
    2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis
    		[PMID: 26928286]
    Neutrophil IC50
    3.2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry
    		[PMID: 24388689]
    Neutrophil IC50
    3.2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis
    		[PMID: 26928286]
    Neutrophil IC50
    5.62 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis
    		[PMID: 23647825]
    Neutrophil IC50
    6.3 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry
    		[PMID: 25419616]
    Non-small cell lung cancer cell line GI50
    2.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel non-small cell lung cancer (8 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel non-small cell lung cancer (8 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    OS-RC-2 IC50
    14 μM
    Compound: Sora
    Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    OS-RC-2 IC50
    15 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    		[PMID: 29786436]
    OS-RC-2 IC50
    16 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    OS-RC-2 IC50
    7 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    		[PMID: 29297688]
    OS-RC-2 IC50
    7 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay
    		[PMID: 29517908]
    OS-RC-2 IC50
    ~ 9 μM
    Compound: Sorafenib
    Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 48 hrs
    Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 48 hrs
    		[PMID: 38354523]
    OVCAR-3 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition
    Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    OVCAR-3 IC50
    12 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    OVCAR-3 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-3 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-4 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition
    Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    OVCAR-4 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    OVCAR-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-5 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-5 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-5 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-5 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-5 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-5 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-8 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-8 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-8 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-8 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-8 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-8 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    PANC-1 IC50
    0.15 μM
    Compound: Sorafenib
    Antiproliferative activity against human PANC1 cells
    Antiproliferative activity against human PANC1 cells
    		[PMID: 30503935]
    PANC-1 IC50
    11.5 μM
    Compound: Sorafenib
    Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 27503679]
    PANC-1 IC50
    12.3 μM
    Compound: Sorafenib
    Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
    Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    PANC-1 IC50
    20 μM
    Compound: Sorafenib
    Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    PANC-1 IC50
    9.32 μM
    Compound: Sorafenib
    Growth inhibition of human PANC1 cells after 48 hrs by MTT assay
    Growth inhibition of human PANC1 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    PC-3 GI50
    1.99 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    PC-3 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human PC3 cells after 48 hrs by SRB method
    Cytotoxicity against human PC3 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition
    Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    PC-3 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    PC-3 IC50
    10.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells by MTT assay
    Antiproliferative activity against human PC3 cells by MTT assay
    		10.1039/C4MD00536H
    PC-3 IC50
    11.53 μM
    Compound: SOR
    Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    PC-3 IC50
    15.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    PC-3 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    PC-3 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    PC-3 IC50
    24.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 24440479]
    PC-3 IC50
    24.2 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    PC-3 IC50
    3.03 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 28340913]
    PC-3 IC50
    3.18 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    PC-3 IC50
    3.24 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    PC-3 IC50
    4.13 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    PC-3 IC50
    6.3 μM
    Compound: 1
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34634618]
    PC-3 IC50
    6.8 μM
    Compound: Sorafenib, Nexavar, BAY-439006
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 23021967]
    PC-3 IC50
    8.08 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27043268]
    PC-3 IC50
    9.77 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    PLC-PRF-5 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    PLC-PRF-5 IC50
    29.9 μM
    Compound: Sorafenib
    Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 28109948]
    PLC-PRF-5 IC50
    7.51 μM
    Compound: Sor
    Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    PLC-PRF-5 IC50
    8.3 μM
    Compound: BAY-439006, Nexavar
    Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition
    Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition
    		[PMID: 21531053]
    Panel CNS (Carcinoma cell lines) GI50
    2.33 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel CNS (6 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel CNS (6 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel breast (Carcinoma cell lines) GI50
    2.17 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel breast (6 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel breast (6 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel colon (Carcinoma cell lines) GI50
    2.19 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel colon (7 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel colon (7 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel leukemia (Carcinoma cell lines) GI50
    2.43 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel leukemia (5 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel leukemia (5 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel melanoma (Carcinoma cell lines) GI50
    1.87 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel melanoma (9 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel melanoma (9 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel ovarian (Carcinoma cell lines) GI50
    2.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel ovarian (7 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel ovarian (7 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel prostate (Carcinoma cell lines) GI50
    2.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel prostate (2 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel prostate (2 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    Panel renal (Carcinoma cell lines) GI50
    2.94 μM
    Compound: Sorafenib
    Antiproliferative activity against human Panel renal (8 Carcinoma cell lines) assessed as reduction in mean cell growth
    Antiproliferative activity against human Panel renal (8 Carcinoma cell lines) assessed as reduction in mean cell growth
    		[PMID: 27155467]
    RKO IC50
    24.18 μM
    Compound: Sorafenib
    Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    RPMI-8226 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    RPMI-8226 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    RPMI-8226 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    RPMI-8226 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    RPMI-8226 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    RS4-11 GI50
    9.3 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay
    		[PMID: 23618709]
    RS4-11 GI50
    9.4 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method
    Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method
    		[PMID: 21708468]
    RS4-11 IC50
    2 nM
    Compound: Sorafenib
    Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    		[PMID: 19654408]
    RS4-11 IC50
    3.2 nM
    Compound: Sorafenib
    Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    		[PMID: 19654408]
    RS4-11 IC50
    > 5 μM
    Compound: 2
    Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    RXF 393 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human RXF 393 cells assessed as reduction in cell growth
    Antiproliferative activity against human RXF 393 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human RXF 393 cells assessed as cell growth inhibition
    Antiproliferative activity against human RXF 393 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    RXF 393 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    RXF 393 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    Raji IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    Raji IC50
    3.94 μM
    Compound: Sor
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Ramos IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    Rhabdomyosarcoma cell CC50
    7.05 μM
    Compound: Sorafenib
    Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay
    Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay
    		[PMID: 27288186]
    SF-268 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SF268 cells after 48 hrs by SRB method
    Cytotoxicity against human SF268 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SF-268 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SF-268 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SF-268 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SF-268 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SF-268 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SF-295 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SF295 cells after 48 hrs by SRB method
    Cytotoxicity against human SF295 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition
    Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SF-295 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SF-295 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SF-539 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SF539 cells after 48 hrs by SRB method
    Cytotoxicity against human SF539 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition
    Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SF-539 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SF-539 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SGC-7901 IC50
    10.37 μM
    Compound: Sorafenib
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    SGC-7901 IC50
    101 μM
    Compound: Sorafenib
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    SGC-7901 IC50
    102 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SGC-7901 IC50
    11.5 μM
    Compound: Sorafenib
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    SGC-7901 IC50
    6.9 μM
    Compound: Sorafenib
    Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    SGC-7901 IC50
    8.84 μM
    Compound: Sorafenib
    Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    SH-SY5Y IC50
    19.54 μM
    Compound: Sorafenib
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    SH-SY5Y IC50
    27.71 μM
    Compound: Sorafenib
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    SH-SY5Y IC50
    5.73 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SH-SY5Y IC50
    5.73 μM
    Compound: Sorafenib
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    SH-SY5Y IC50
    > 100 μM
    Compound: Sorafenib
    Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    SK-BR-3 IC50
    5.21 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SK-HEP1 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SK-HEP1 IC50
    1.98 μM
    Compound: sorafenib
    Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    SK-HEP1 IC50
    11.7 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs
    Anti-hepatoma activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs
    		[PMID: 38521176]
    SK-HEP1 IC50
    7.3 μM
    Compound: 1
    Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34634618]
    SK-HEP1 IC50
    8.37 μM
    Compound: Sor
    Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SK-HEP1 IC50
    8.63 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 37182331]
    SK-HEP1 IC50
    9.64 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32791397]
    SK-MEL IC50
    10 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 33882233]
    SK-MEL-2 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-MEL-2 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-MEL-2 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-MEL-2 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-MEL-2 IC50
    11.35 μM
    Compound: Sorafenib
    Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    SK-MEL-2 IC50
    11.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    SK-MEL-2 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-MEL-2 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-MEL-28 EC50
    1.3 μM
    Compound: 1, sorafenib, BAY-439006
    Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay
    Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay
    		[PMID: 18942827]
    SK-MEL-28 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method
    Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition
    Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SK-MEL-28 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    SK-MEL-28 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-MEL-28 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-MEL-28 IC50
    9.45 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30955995]
    SK-MEL-28 IC50
    9.49 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 38744089]
    SK-MEL-30 IC50
    3900 nM
    Compound: 1
    Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay
    Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 29461827]
    SK-MEL-5 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method
    Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell growth
    Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-MEL-5 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-MEL-5 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-MEL-5 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    SK-OV-3 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-OV-3 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-OV-3 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-OV-3 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-OV-3 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-OV-3 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-OV-3 IC50
    9.25 μM
    Compound: Sorafenib
    Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    SMMC-7721 IC50
    0.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells
    Antiproliferative activity against human SMMC7721 cells
    		[PMID: 30503935]
    SMMC-7721 IC50
    0.37 μM
    Compound: Sorafenib
    Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25982075]
    SMMC-7721 IC50
    0.65 μM
    Compound: BAY-43-9006
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    		[PMID: 26342134]
    SMMC-7721 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26753815]
    SMMC-7721 IC50
    10.61 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    SMMC-7721 IC50
    17.3 μM
    Compound: sorafenib
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    SMMC-7721 IC50
    18.7 μM
    Compound: Sorafenib
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    SMMC-7721 IC50
    2.37 μM
    Compound: sorafenib
    Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    SMMC-7721 IC50
    4.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    SMMC-7721 IC50
    6.23 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    		[PMID: 22721924]
    SMMC-7721 IC50
    8.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36745506]
    SMMC-7721 IC50
    9.86 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SMMC-7721 IC50
    9.96 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 25637123]
    SMMC-7721 IC50
    > 10 μM
    Compound: Sorafenib
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32842729]
    SN12C GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SN12C cells after 48 hrs by SRB method
    Cytotoxicity against human SN12C cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SN12C cells assessed as cell growth inhibition
    Antiproliferative activity against human SN12C cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SN12C IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SN12C IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SNB-19 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human SNB19 cells after 48 hrs by SRB method
    Cytotoxicity against human SNB19 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SNB-19 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SNB-19 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SNB-19 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SNB-19 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SNB-19 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SNB-75 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human SNB75 cells after 48 hrs by SRB method
    Cytotoxicity against human SNB75 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth
    Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth
    		[PMID: 27155467]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition
    Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SNB-75 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SNB-75 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    SNB-75 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SNU-387 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SNU-387 IC50
    12.33 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    SNU-387 IC50
    258.91 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNU-387 cells by MTT assay
    Antiproliferative activity against human SNU-387 cells by MTT assay
    		[PMID: 34128674]
    SNU-387 IC50
    8.29 μM
    Compound: Sor
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SNU-398 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SNU-398 IC50
    3.38 μM
    Compound: Sor
    Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SR GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human SR cells after 48 hrs by SRB method
    Cytotoxicity against human SR cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SR GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SR GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SR GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SR cells assessed as cell growth inhibition
    Antiproliferative activity against human SR cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SR IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SR IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SU-DHL-6 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SU-DHL-6 IC50
    3.82 μM
    Compound: Sor
    Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SW-620 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SW620 cells after 48 hrs by SRB method
    Cytotoxicity against human SW620 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW-620 cells assessed as cell growth inhibition
    Antiproliferative activity against human SW-620 cells assessed as cell growth inhibition
    		[PMID: 38850857]
    SW-620 IC50
    2.3 μM
    Compound: Sorafenib
    Cytotoxicity against human SW620 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human SW620 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    		[PMID: 38354306]
    SW-620 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SW-620 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SW480 GI50
    14.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    SW480 GI50
    15.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    Sf9 IC50
    0.003 μM
    Compound: BAY-439006, 3
    Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    0.018 μM
    Compound: BAY-439006, 3
    Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    0.02 μM
    Compound: 2, BAY-43-9006
    Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis
    Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis
    		[PMID: 23618709]
    Sf9 IC50
    0.042 μM
    Compound: 2
    Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay
    		[PMID: 26081023]
    Sf9 IC50
    0.043 μM
    Compound: 2, sorafenib
    Inhibition of human BRAF V600E mutant expressed in SF9 cells
    Inhibition of human BRAF V600E mutant expressed in SF9 cells
    		[PMID: 18473434]
    Sf9 IC50
    0.044 μM
    Compound: 2
    Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay
    Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay
    		[PMID: 26081023]
    Sf9 IC50
    0.054 μM
    Compound: 2, BAY-43-9006
    Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis
    Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis
    		[PMID: 23618709]
    Sf9 IC50
    0.054 μM
    Compound: BAY-439006, 3
    Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay
    Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    0.057 μM
    Compound: Sorafenib
    Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay
    Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay
    		[PMID: 30826508]
    Sf9 IC50
    0.1 μM
    Compound: I; BAY 43-9006
    Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay
    Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay
    		[PMID: 31284081]
    Sf9 IC50
    14520 nM
    Compound: 59
    Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay
    Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay
    		[PMID: 31622096]
    Sf9 IC50
    3.8 μM
    Compound: 2
    Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay
    		[PMID: 26081023]
    Sf9 IC50
    3.8 μM
    Compound: 2, BAY-43-9006
    Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis
    Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis
    		[PMID: 23618709]
    Sf9 IC50
    3.8 μM
    Compound: BAY-439006, 3
    Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    90 nM
    Compound: sorafenib
    Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay
    Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay
    		[PMID: 23562241]
    Sf9 IC50
    < 100 nM
    Compound: Sorafenib
    Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay
    Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay
    		[PMID: 23442188]
    Sf9 IC50
    < 100 nM
    Compound: Sorafenib
    Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay
    Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay
    		[PMID: 23442188]
    T-24 IC50
    5.31 μM
    Compound: Cpd S
    Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
    Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
    		[PMID: 32827851]
    T47D GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human T47D cells after 48 hrs by SRB method
    Cytotoxicity against human T47D cells after 48 hrs by SRB method
    		[PMID: 26590508]
    T47D GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    T47D GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    T47D GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    T47D IC50
    0.61 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    T47D IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    T47D IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    T47D IC50
    1.6 μM
    Compound: I; BAY 43-9006
    Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay
    		[PMID: 31284081]
    T47D IC50
    6.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    THLE-2 CC50
    19.6 μM
    Compound: Sorafenib
    Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability by CCK-8 assay
    Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability by CCK-8 assay
    		[PMID: 38521176]
    THP-1 IC50
    0.31 μM
    Compound: 2
    Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    THP-1 IC50
    0.31 μM
    Compound: 2
    Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    TK-10 GI50
    3.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    TK-10 GI50
    3.98 μM
    Compound: Sorafenib
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    TK-10 GI50
    3.98 μM
    Compound: Sorafenib
    Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    TK-10 IC50
    3.98 μM
    Compound: Sorafenib
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    TK-10 IC50
    3.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    TPC1 EC50
    2.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human TPC1 cells
    Antiproliferative activity against human TPC1 cells
    		[PMID: 22559926]
    TT IC50
    1.4 nM
    Compound: sorafenib
    Antiproliferative activity against human TT cells after 13 days by fluorescence assay
    Antiproliferative activity against human TT cells after 13 days by fluorescence assay
    		[PMID: 18849971]
    U-251 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human U251 cells after 48 hrs by SRB method
    Cytotoxicity against human U251 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    U-251 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    U-251 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    U-251 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    U-251 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    U-251 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    U-251 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    U-251 IC50
    24.71 μM
    Compound: Sorafenib
    Cytotoxicity against human U251 cells after 48 hrs by MTT assay
    Cytotoxicity against human U251 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    U-87MG ATCC IC50
    1.282 μM
    Compound: Sorafenib
    Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay
    		[PMID: 37216813]
    U-87MG ATCC IC50
    12.67 μM
    Compound: Sorafenib
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36508995]
    U-87MG ATCC IC50
    15.57 μM
    Compound: Sorafenib
    Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
    Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    U-87MG ATCC IC50
    21.07 μM
    Compound: Sorafenib
    Cytotoxicity against human U87 cells after 48 hrs by MTT assay
    Cytotoxicity against human U87 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    U-87MG ATCC IC50
    8.46 μM
    Compound: Sorafenib
    Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    U-937 GI50
    2.34 μM
    Compound: Sorafenib
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    		[PMID: 29459144]
    U-937 GI50
    2.74 μM
    Compound: Sorafenib
    Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24878193]
    U-937 GI50
    2.74 μM
    Compound: Sorafenib
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    		[PMID: 26318067]
    U-937 GI50
    2.85 μM
    Compound: Sorafenib
    Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay
    Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay
    		[PMID: 22014755]
    U-937 GI50
    3.4 μM
    Compound: 2
    Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    U-937 GI50
    3.4 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay
    Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay
    		[PMID: 23618709]
    U-937 GI50
    3.4 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method
    Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method
    		[PMID: 21708468]
    U-937 IC50
    > 3 μM
    Compound: Sorafenib
    Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    U-937 IC50
    > 5 μM
    Compound: 2
    Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    UACC-257 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human UACC257 cells after 48 hrs by SRB method
    Cytotoxicity against human UACC257 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    UACC-257 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    UACC-257 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    UACC-257 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    UACC-257 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    UACC-257 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    UACC-62 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    UACC-62 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    UACC-62 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    UACC-62 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    UACC-62 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    UACC-62 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    UO-31 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human UO31 cells after 48 hrs by SRB method
    Cytotoxicity against human UO31 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    UO-31 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    UO-31 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    UO-31 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    UO-31 IC50
    2.51 μM
    Compound: 1
    Antiproliferative activity against human UO31 cells
    Antiproliferative activity against human UO31 cells
    		[PMID: 30216849]
    UO-31 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    UO-31 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    UO-31 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    WI-38 GI50
    > 20 μM
    Compound: Sorafenib
    Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    WI-38 IC50
    10.65 μM
    Compound: SOR
    Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    WI-38 IC50
    14.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human WI-38 cells measured by MTT assay
    Antiproliferative activity against human WI-38 cells measured by MTT assay
    		[PMID: 35764033]
    WI-38 IC50
    17.7 μM
    Compound: Sorafenib
    Cytotoxicity against human WI-38 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
    		[PMID: 38850857]
    WI-38 IC50
    7.54 μM
    Compound: Sorafenib
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    WI-38 IC50
    8.42 μM
    Compound: Sorafenib
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    WI-38 IC50
    > 30 μM
    Compound: Sorafenib
    Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    WISH IC50
    17.54 μM
    Compound: Sorafenib
    Cytotoxicity against human WISH cells assessed as cell growth inhibition
    Cytotoxicity against human WISH cells assessed as cell growth inhibition
    		[PMID: 37453330]
    WM 266-4 GI50
    4.5 μM
    Compound: Sorafenib
    Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay
    Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay
    		[PMID: 20199087]
    WM 266-4 GI50
    4.933 μM
    Compound: 2
    Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay
    Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay
    		[PMID: 20148563]
    WM 266-4 GI50
    8.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay
    Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay
    		[PMID: 23025996]
    WM 266-4 GI50
    8.12 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay
    Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay
    		[PMID: 22583669]
    WM 266-4 GI50
    8.3 μM
    Compound: Sorafenib
    Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay
    Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay
    		[PMID: 22361686]
    WM 266-4 IC50
    0.06 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay
    Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay
    		[PMID: 25496804]
    WM 266-4 IC50
    5 μM
    Compound: Sorafenib
    Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay
    Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay
    		[PMID: 19323560]
    WM164 IC50
    4.9 μM
    Compound: sorafenib, velcade
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    		[PMID: 17561392]
    WM164 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    		[PMID: 20056548]
    ZR-75-30 IC50
    2.96 μM
    Compound: Sorafenib
    Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay
    Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    In Vitro

    Sorafenib (0.01-3 μM; 2 h) selectively inhibits the MAPK pathway, while has no effect on the PKB pathway in MDA-MB-231 cells[1].
    Sorafenib (0.01-15 μM; 2 h) inhibits MEK 1/2 and ERK 1/2 phosphorylation in MDA-MB-231 human breast carcinoma cells (IC50s of 40 and 90 nmol/L, respectively), ERK 1/2 phosphorylation in BxPC-3, LOX, HCT 116, HT-29, Colo-205, and Mia PaCa-2 cells, but does not inhibit ERK 1/2 phosphorylation in A549 and NCI-H460 cells[1].
    Sorafenib (0.01-10 μM; 72 h) inhibits proliferation of MDA-MB-231 cells with an IC50 of 2600 nmol/L)[1].
    Sorafenib (8.9 μM) exhibits an IC50 of 8.9 μM in human colorectal carcinoma HCT8 and HT29 cell lines, and causes marked antagonism with oxaliplatin and cisplatin across all tested incubation schedules, reducing platinum-induced cytotoxicity[2].
    Sorafenib (4-24 μM; 24 h) reduces expression of p21Cip1 protein and cyclin D1 expression in HCT8 and HT29 cells when incubated simultaneously with Oxaliplatin (HY-17371) or Cisplatin (HY-17394)[2].
    Sorafenib (24 μM; 4 h) significantly reduces Cisplatin- and Oxaliplatin-induced DNA adduct levels in HCT8 and HT29 cells when applied simultaneously, but does not affect adduct levels or repair when applied consecutively[2].
    Sorafenib (0-20 μmol/L; 24-72 h) inhibits the proliferation of HCCLM3, HepG2, and rat Morris hepatoma 3924A (MH) HCC cell lines in a time- and dose-dependent manner[3].
    Sorafenib (0-20 μmol/L; 2-24 h) durably inhibits phosphorylation of STAT3Y705 and S727, ERK1/2, and Akt, and reduces cyclin D1 expression, without altering JAK2 or SHP2 phosphorylation, in HCCLM3, HepG2, and MH HCC cell lines[3].
    Sorafenib (5 μM; 48 h) significantly increases clonogenicity, enhances tumoursphere formation, and upregulates cancer stem cell-associated pluripotency markers Sox2 and Oct4 in A549, NCI-H460, and NCI-H1299 NSCLC cells[5].
    Sorafenib (5 μM; 48 h) increases ALDH-positive cancer stem cell populations in A549 NSCLC cells[5].
    Sorafenib (5 μM; 48 h) significantly enhances migration capacity in NCI-H460 NSCLC cells[5].
    Sorafenib (5 μM; 48 h) induces epithelial-to-mesenchymal transition in NCI-H460 NSCLC cells via downregulation of E-cadherin and upregulation of N-cadherin, vimentin, and MMP2, and activates the AKT pathway via increased AKT phosphorylation[5].
    Sorafenib (5 μM; 48 h) upregulates STMN1, FOXM1, and E2F1 expression at the mRNA and protein levels in NCI-H460 and NCI-H1299 NSCLC cells[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Sorafenib Related Antibodies

    Western Blot Analysis[1]

    Cell Line: MDA-MB-231
    Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM
    Incubation Time: 2 h
    Result: Dose-dependently inhibited basal MEK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 40 nmol/L.
    Inhibited ERK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 90 nmol/L.
    Showed no effect on PKB phosphorylation in MDA-MB-231 cells.
    Completely blocked activation of the MAPK pathway.

    Cell Proliferation Assay[1]

    Cell Line: MDA-MB-231
    Concentration: 0.01-10 μM
    Incubation Time: 72 h
    Result: Inhibited MDA-MB-231 cell proliferation with an IC50 of 2600 nmol/L.

    Western Blot Analysis[2]

    Cell Line: HCT8 and HT29 cells
    Concentration: 4, 24 μM
    Incubation Time: 24 h
    Result: Reduced p21Cip1 protein expression induced by Oxaliplatin or Cisplatin at 4 μM when applied simultaneously.
    Completely inhibited platinum-induced p21Cip1 expression at 24 μM when applied simultaneously.
    Reduced cyclin D1 expression enhanced by Oxaliplatin when applied simultaneously.
    Reduced cdc2 expression enhanced by cisplatin when applied simultaneously.
    Showed no effect on these protein levels when applied consecutively after platinum treatment.

    Cell Proliferation Assay[3]

    Cell Line: HCCLM3, HepG2, MH cells
    Concentration: 0, 0.05, 0.1, 1, 5, 10, 20 μmol/L
    Incubation Time: 24, 48, 72 h
    Result: Inhibited HCC cell growth in a time- and dose-dependent manner across all three cell lines.
    Increased inhibition rates with both higher sorafenib concentrations and longer incubation periods.
    Exhibited the strongest inhibition at 20 μmol/L after 72 h of treatment.

    Western Blot Analysis[3]

    Cell Line: HCCLM3, HepG2, MH cells
    Concentration: 0, 2, 5, 10, 20 μmol/L
    Incubation Time: 2 h (0-20 μmol/L); 2, 6, 12, 24 h (10 μmol/L)
    Result: Inhibited phosphorylation of STAT3 at Y705 and S727, as well as phosphorylation of ERK1/2, in a dose-dependent manner after 2 h of treatment across all three cell lines.
    Durably inhibited phosphorylation of STAT3 (Y705 and S727) and ERK1/2 for up to 24 h at 10 μmol/L, while total STAT3 protein levels and JAK2 phosphorylation remained unchanged.
    Inhibited Akt phosphorylation primarily at 2 μmol/L after 2 h and reduced cyclin D1 protein expression, while leaving SHP2 phosphorylation unchanged.

    Western Blot Analysis[5]

    Cell Line: A549, NCI-H460, NCI-H1299 cells
    Concentration: 5 μM
    Incubation Time: 48 h
    Result: Upregulated expression levels of Sox2 and Oct4 in all three NSCLC cell lines compared to untreated controls.
    Markedly decreased the epithelial marker E-cadherin compared to untreated controls.
    Correspondingly increased mesenchymal markers N-cadherin, vimentin, and MMP2 compared to untreated controls. Upregulated the expression of phosphorylated AKT in NCI-H460 cells compared to untreated controls.
    Showed no obvious effect on phosphorylated JNK expression compared to untreated controls in NCI-H460 cells.
    Showed an increase in phosphorylated ERK expression compared to untreated controls in NCI-H460 cells.

    Cell Migration Assay [5]

    Cell Line: NCI-H460 cells
    Concentration: 5 μM
    Incubation Time: 48 h
    Result: Resulted in the strongest enhancement of cell migration.
    Showed a higher CI (the capacity for cell migration) slope indicating faster migration velocity compared to DMSO-treated controls.

    Western Blot Analysis[5]

    Cell Line: NCI-H460, NCI-H1299 cells
    Concentration: 5 μM
    Incubation Time: 48 h
    Result: Upregulated STMN1, FOXM1, and E2F1 protein expression in both cell lines compared to untreated controls.
    In Vivo

    Sorafenib (7.5-60 mg/kg; p.o.; daily for 5 or 9 days) inhibits tumor growth, suppresses RAF/MEK/ERK signaling, and reduces angiogenesis in mouse breast, colon, and NSCLC xenograft models, with no observed toxicity[1].
    Sorafenib (30 mg/kg; i.g.; once daily; once daily from day 17 to day 38) inhibits hepatocellular carcinoma tumor growth and metastasis in an orthotopic rat Morris Hepatoma (MH) model, while inducing tumor apoptosis and suppressing STAT3, Akt, and ERK phosphorylation[3].
    Sorafenib (10 mg/kg; p.o.; daily; 2 weeks) exhibits antineoplastic activity in Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma in albino rats[4].
    Sorafenib (4 mg/kg; i.p.; twice a week for 4 weeks) in combined with intratumoral siTUC338 significantly reduces tumor volume in mouse HepG2/Sor xenografts via upregulation of RASAL1[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female NCr-nu/nu mice subcutaneously injected with MDA-MB-231 cells [1]
    Dosage: 7.5; 15; 30; 60 mg/kg
    Administration: p.o.; daily for 5 or 9 days
    Result: Produced a 42% reduction in mean tumor weight after 9 days at 30 mg/kg .
    Inhibited microvessel area (MVA) and microvessel density (MVD) in tumors, induced extensive tumor necrosis, reduced phosphorylated ERK 1/2 (pERK) levels, and decreased Ki-67 staining at 30 or 60 mg/kg daily for 5 days.
    Caused no toxicity in treated group.
    Animal Model: Female NCr-nu/nu mice subcutaneously injected with Colo-205, HT-29, and DLD-1 cells[1]
    Dosage: 7.5; 15; 30; 60 mg/kg
    Administration: p.o.; daily for 5 or 9 days
    Result: Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
    Reduced MVA to ~0.4% and MVD to ~80/mm2 at 30 mg/kg daily for 5 days, and reduced MVA to ~0.2% and MVD to ~50/mm2 at 60 mg/kg daily for 5 days relative to vehicle controls.
    Detected no reduction in pERK levels at 30 or 60 mg/kg daily for 5 days.
    Caused no toxicity in any treated group.\n
    Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
    Inhibited MVA and MVD in tumors by 50 to 80%, reduced pERK levels, and inhibited MEK 1/2 phosphorylation at 30 or 60 mg/kg daily for 5 days.
    Caused no toxicity in any treated group.
    Animal Model: Female NCr-nu/nu mice subcutaneously injected with NCI-H460, and A549 cells[1]
    Dosage: 7.5; 15; 30; 60 mg/kg
    Administration: p.o.; daily; 9 days
    Result: Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily.
    Caused no toxicity in any treated group.
    Animal Model: Male ACI rats (200-220 g) orthotopic implantated with Morris Hepatoma (MH) fragments[3]
    Dosage: 30 mg/kg
    Administration: i.g.; once daily from day 17 to day 38
    Result: Reduced mean tumor volume to 351.26 mm3 in early treatment group and 2248.33 mm3 in late treatment group.
    Prevented lung, lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in early treatment group, and lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in late treatment group.
    Induced tumor cell apoptosis with an apoptosis index of 0.909.
    Reduced phosphorylation of STAT3 (Y705 and S727), Akt, and ERK in tumor tissue.
    Decreased cyclin D1 expression.
    Did not affect STAT3 mRNA levels, JAK2 phosphorylation, or SHP2 phosphorylation in tumor tissue.
    Animal Model: Male albino rats (100-120 g) with Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma)[4]
    Dosage: 10 mg/kg
    Administration: p.o.; daily; 2 weeks
    Result: Improved survival rate to 83.3%.
    Significantly decreased liver index below normal control group level.
    Reduced hepatocellular foci size by 34.8% compared to the DENA-only group.
    Lowered total hepatic foci count to 10 compared to 18 in the DENA-only group.
    Decreased cyclin D1 and β-catenin gene expression.
    Reduced liver Bcl-2 protein and liver glutathione (GSH) levels.
    Animal Model: Male nude mice (4-6 weeks, 18-20 g) subcutaneously injected with HepG2/Sor cells[6]
    Dosage: 4 mg/kg
    Administration: i.p.; twice a week; 4 weeks
    Result: Achieved statistically significantly lower mean tumor volume compared to sorafenib combined with saline or siNC.
    Significantly downregulated TUC338 expression in tumor tissue relative to control groups.
    Significantly upregulated RASAL1 mRNA and protein levels in tumor tissue relative to control groups.
    Clinical Trial
    Molecular Weight

    464.83

    Formula

    C21H16ClF3N4O3
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 45 mg/mL (96.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1513 mL 10.7566 mL 21.5132 mL
    5 mM 0.4303 mL 2.1513 mL 4.3026 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  2% DMSO    40% PEG300    5% Tween-80    53% Saline

      Solubility: ≥ 3 mg/mL (6.45 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (4.47 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.85%

    SDS (597 KB)

    COA (244 KB) HNMR (156 KB) RP-HPLC (253 KB) MS (68 KB) Elemental Analysis Report (102 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1513 mL 10.7566 mL 21.5132 mL 53.7831 mL
    5 mM 0.4303 mL 2.1513 mL 4.3026 mL 10.7566 mL
    10 mM 0.2151 mL 1.0757 mL 2.1513 mL 5.3783 mL
    15 mM 0.1434 mL 0.7171 mL 1.4342 mL 3.5855 mL
    20 mM 0.1076 mL 0.5378 mL 1.0757 mL 2.6892 mL
    25 mM 0.0861 mL 0.4303 mL 0.8605 mL 2.1513 mL
    30 mM 0.0717 mL 0.3586 mL 0.7171 mL 1.7928 mL
    40 mM 0.0538 mL 0.2689 mL 0.5378 mL 1.3446 mL
    50 mM 0.0430 mL 0.2151 mL 0.4303 mL 1.0757 mL
    60 mM 0.0359 mL 0.1793 mL 0.3586 mL 0.8964 mL
    80 mM 0.0269 mL 0.1345 mL 0.2689 mL 0.6723 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Sorafenib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Sorafenib284461-73-0Bay 43-9006RafVEGFRFLT3AutophagyApoptosisSTATAktMMPCadherinp38 MAPKERKMEKPI3KPARPBcl-2 FamilyRaf kinasesVascular endothelial growth factor receptorCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3PKBProtein kinase BMatrix metalloproteinasesExtracellular signal regulated kinasesMitogen-activated protein kinase kinaseMAPKKMAP2KPhosphoinositide 3-kinasepoly ADP ribose polymeraseVEGFR-2Flt-3c-KITPI3K/Akt pathwayMDA-MB-231 human breast carcinoma cellsPDGFR-βBRAFRAF/MEK/ERK pathwayRaf-1VEGFR-3Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Sorafenib
    Cat. No.:
    HY-10201
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (597 KB) Français - FR (597 KB) Deutsch - DE (597 KB) Norwegian - NO (597 KB) Español - ES (597 KB) Swedish - SV (597 KB) Italian - IT (597 KB) Korean - KR (597 KB) Portuguese - PT (597 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.